Development of a stability-indicating high performance liquid chromatography method for assay of erythromycin ethylsuccinate in powder for oral suspension dosage form
Name
Kamarei--Development of a sta.pdf
Size
712.27 KB
Format
Adobe PDF
Checksum (MD5)
4b9cd9d5ebf9620c8c68ec5dcd830478
Author(s)
Kamarei, Fahimeh
Movaghari, Farshid
Ghaffari, Alireza
Soltani Bozchalooi, Iman
Zamani, Ali
Jabbari, Ali
Date Issued
January 2011
Journal
Arabian Journal of Chemistry
Publisher
Elsevier
Citation
Kamarei, Fahimeh, Farshid Movaghari, Alireza Ghaffari, Iman Soltani Bozchalooi, Ali Zamani, and Ali Jabbari. “Development of a Stability-Indicating High Performance Liquid Chromatography Method for Assay of Erythromycin Ethylsuccinate in Powder for Oral Suspension Dosage Form.” Arabian Journal of Chemistry 7, no. 6 (December 2014): 1079–1085.
Version
Final published version
Abstract
In this study an effective method was developed to assay erythromycin ethylsuccinate for an oral suspension dosage form. The chromatographic separation was achieved on an X-Terra[superscript ™] C[subscript 18] analytical column. A mixture of acetonitrile–ammonium dihydrogen phosphate buffer (0.025 mol L[superscript -1]) (60:40, V/V) (pH 7.0) was used as the mobile phase, effluent flow rate monitored at 1.0 mL min[superscript −1], and UV detection at 205 nm. In forced degradation studies, the effects of acid, base, oxidation, UV light and temperature were investigated showing no interference in the peak of drug. The proposed method was validated in terms of specificity, linearity, robustness, precision and accuracy. The method was linear at concentrations ranging from 400 to 600 μg mL[superscript −1], precise (intra- and inter-day relative standard deviations <0.65), accurate (mean recovery; 99.5%). The impurities and degradation products of erythromycin ethylsuccinate were selectively determined with good resolution in both the raw material and the final suspension forms. The method could be useful for both routine analytical and quality control assays of erythromycin ethylsuccinate in commercial powder for an oral suspension dosage form and it could be a very powerful tool to investigate the chemical stability of erythromycin ethylsuccinate.
MIT Department
Massachusetts Institute of Technology. Department of Mechanical Engineering
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivatives
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.arabjc.2011.01.004
